

RESEARCH ARTICLE

Open Access



A comparison of the enzymatic properties of three recombinant isoforms of thrombolytic and antibacterial protein—Destabilase-Lysozyme from medicinal leech

Alexey S. Kurdyumov^{1*}, Valentin A. Manuvera¹, Isolda P. Baskova² and Vassili N. Lazarev¹

Abstract

Background: Destabilase-Lysozyme (mIDL) is a multifunctional i-type enzyme that has been found in the secretions from the salivary glands of medicinal leeches. mIDL has been shown to exhibit isopeptidase, muramidase and antibacterial activity. This enzyme attracts interest because it expresses thrombolytic activity through isopeptidolysis of the ϵ -(γ -Glu)-Lys bonds that cross-link polypeptide chains in stabilised fibrin. To date, three isoforms of mIDL have been identified.

The enzymatic properties of pure mIDL isoforms have not yet been described because only destabilase complexes containing other proteins could be isolated from the salivary gland secretion and because low product yield from the generation of recombinant proteins has made comprehensive testing difficult.

Results: In the present study, we optimised the procedures related to the expression, isolation and purification of active mIDL isoforms (mIDL-Ds1, mIDL-Ds2, mIDL-Ds3) using an *Escherichia coli* expression system, and we detected and compared their muramidase, lytic, isopeptidase and antimicrobial activities. After optimisation, the product yield was 30 mg per litre of culture. The data obtained in our study led to the suggestion that the recombinant mIDL isoforms isolated from inclusion bodies form stable oligomeric complexes. Analyses of the tested activities revealed that all isoforms exhibited almost identical patterns of pH and ionic strength effects on the activities. We determined that mIDL-Ds1, 2, 3 possessed non-enzymatic antibacterial activity independent of their muramidase activity. For the first time, we demonstrated the fibrinolytic activity of the recombinant mIDL and showed that only intact proteins possessed this activity, suggesting their enzymatic nature.

Conclusions: The recombinant Destabilase-Lysozyme isoforms obtained in our study may be considered potential thrombolytic agents that act through a mechanism different from that of common thrombolytics.

Keywords: Destabilase-Lysozyme, Recombinant protein, Thrombolysis, Isopeptidase, Antimicrobial activity

* Correspondence: aleks-kuzmaland@bk.ru

¹Federal Research and Clinical Center of Physical-Chemical Medicine, Malaya Pirogovskaya, 1a, Moscow 119435, Russia

Full list of author information is available at the end of the article



Background

The use of blood-sucking leeches for medical purposes in humans has been known since ancient times [1, 2]. The leeches were mainly used for bloodletting because evolutionary adaptations of their feeding apparatus promote the inhibition of haemostasis and blood coagulation [3–5]. The composition of leech salivary gland secretions plays a major role in this inhibition [3, 6–8]. Moreover, in 1948, the salivary gland secretions of leeches were shown to have thrombolytic activity [9]. Decades later, in 1984, Baskova and Nikonov revealed that destabilised fibrin depolymerisation occurred after the application of leech salivary gland secretions on stabilised fibrin plates only [6]. Moreover, the process of fibrinolysis held better on a more stabilized fibrin by factor XIIIa. The authors proposed that leech salivary gland secretions contained an enzyme that caused fibrin depolymerisation via the hydrolysis of ϵ -(γ -Glu)-Lys isopeptide bonds between polypeptide chains in stabilised fibrin. Later, the enzyme that possessed thrombolytic activity was isolated and identified. This enzyme was referred to as destabilase [10].

To demonstrate the isopeptidase activity of destabilase, a synthetic analogue of the dipeptide L- γ -glutamine-p-nitroanilide (L- γ -Glu-pNA) [11] and D-dimer (the final proteolytic degradation product of stabilised fibrin) [12] were used. ϵ -(γ -Glu)-Lys bonds cross-link D-monomers in the D-dimer. Destabilase has been shown to exhibit isopeptidase activity in relation to D-dimers without degrading the fibrinogen and serum albumin [13]. This mechanism was revealed through an analysis of the N-terminal amino acid sequence of the γ -chain in the D-monomer after isopeptidolysis of ϵ -(γ -Glu)-Lys bonds [14].

The thrombolytic activity of destabilase has also been demonstrated in an animal (rat) model with a pre-formed thrombus. The thrombus weight was been found to decrease by 85 and 98 % at 48 and 137 h, respectively, after the intravenous injection of destabilase [15].

In 2000, a comparison of the amino acid sequence of destabilase with the sequences of other known proteins revealed the similarity of its fragment to *Asteria rubens* lysozyme, suggesting that destabilase possesses muramidase activity [16]. Muramidase activity involves the hydrolysis of the β -(1,4)-glycoside bond between N-acetylmuramic acid and N-acetylglucosamine in the bacterial peptidoglycan [17]. The muramidase activity of destabilase was demonstrated by the cell wall disruption of *Micrococcus lysodeikticus* [16]. At the same time, this enzyme with heat-inactivated muramidase activity still exhibited high antimicrobial activity against not only bacteria but also yeasts, fungi, and archaea [13, 18, 19]. It has also been shown that synthetic amphipathic fragments of the destabilase possess antimicrobial activity [18]. Thus, destabilase was the first multifunctional i-type invertebrate lysozyme to be discovered [16], later called Destabilase-Lysozyme

(mIDL) [20]. At the moment, there is only a three-dimensional model of mIDL-Ds2 based on the crystal structure of a highly homologous lysozyme from *Tapes japonica* (TJL) [21]. Among the proteins for which the spatial structure was identified, the primary structure of TJL is mostly similar to the primary structure of destabilase (identity ~46 %). Based upon indirect observations, it was suggested that two distinct active centres in the molecule of TJL are responsible for its isopeptidase and lysozyme activities [22]. 3D model of mIDL-Ds2 structure showed that both functional centers are located relatively close to each other with their overlapping [20].

Because of its properties, mIDL could serve as a potential thrombolytic agent with a low rate of thrombolysis [13].

Previous studies have described the enzymatic properties of mIDL purified from leech salivary gland secretions [10, 16, 23, 24]. The isolation and purification of mIDL directly from the salivary gland secretions of medicinal leeches is a laborious process with a low yield of the final product. Moreover, mIDL is isolated from the salivary gland secretions in the form of a destabilase complex that includes hirudin, 6-keto prostaglandin F_{1 α} and plasma kallikrein inhibitor [23]. Alternatively, recombinant mIDL is used to study the properties of the pure protein. To date, three genes (*Ds-1*, *-2*, *-3*) have been identified that encode three isoforms of the destabilase (*Ds-1*, *-2*, *-3*) [25, 26]. All isoforms were found in *H. medicinalis*. *Ds-1* and *Ds-2* were found by mRNA analysis, *Ds-3* was found by sequencing of CnBr-fragments of destabilase isolated from leech's saliva. The homology between mIDL isoforms varied from approximately 66 to 87 % (Additional file 1: Figure S1). Previously, only two recombinant isoforms of mIDL were expressed in *Escherichia coli* (mIDL-Ds2, 3) [27]. Moreover, mIDL-Ds2 was obtained in a *Spodoptera frugiperda* baculovirus system [28]. Nevertheless, the low final product yield impeded the study of the properties of the pure enzyme. The goal of our study was to generate active mIDL isoforms and compare their enzymatic properties. To this end, we constructed plasmids with sequences that encoded all of the mIDL isoforms. We developed the methods for the expression, isolation and purification of the active mIDL isoforms and detected and compared their lysozyme (muramidase and lytic), isopeptidase and antimicrobial activities. Additionally, to test whether the mIDL isoforms possess antibacterial activity independent of their enzymatic activities, tryptic peptides were generated.

Methods

Generation of the recombinant mIDL isoforms in *E. coli*

DNA fragments that encode the mIDL-Ds1, 2, 3 [25] were *de novo* synthesised from oligonucleotides. These fragments were optimised for expression in *E. coli*. A list of the oligonucleotides and a scheme for synthesising

the fragments are presented in Additional file 2: Table S1 and Additional file 3, respectively. The commercially available plasmid pET-15b (Novagen, USA) was modified by adding new multiple cloning sites. The resulting plasmid was termed pET15MCS (Additional file 3: Figure S2). The DNA fragments encoding the mLDL isoforms and plasmid pET15MCS were treated with the restriction endonucleases BamHI and Sall. The restriction products were ligated. Prepared plasmids were subsequently used for the standard transformation procedure of *E. coli* Top10 cells. PCR selection of the colonies was performed using the oligonucleotides T7 and T7t. Next, the plasmids were extracted and sequenced. Because of the identity of the plasmids that encoded the three mLDL isoforms, we termed them pET15/Dest. A map of the pET15/Dest plasmid is shown in Additional file 3: Figure S3. The *E. coli* strain BL21(DE3)-gold was transformed by the plasmids that encoded the three mLDL isoforms. The transformed cells were plated on a selective solid medium containing ampicillin (150 ng/ml) and then incubated at 37 °C for 16 h. Individual colonies of *E. coli* were inoculated into super broth (SB) medium containing potassium nitrate (2 g/l) and cultured at 37 °C overnight. The cultures were then added to the fresh SB medium containing potassium nitrate at a 1:20 dilution, and the cells were grown until optical density $OD_{600} = 0.8$. Next, lactose was added to a final concentration of 10 mM, and the cultures were incubated again at 37 °C for 6 h. Inclusion bodies were then isolated and solubilised in denaturing buffer containing 8 M urea. The mLDL-Ds1, 2, 3 were isolated using metal chelate affinity chromatography under denaturing conditions (for details, see Additional file 4).

The purified mLDL isoforms were diluted in 8 M urea at a final protein concentration below 1 mg/ml and renatured using stepwise dialysis against the solution containing 20 mM NaH_2PO_4 , 150 mM NaCl with the following decreasing urea concentration: 4, 2, 1, and 0 M. Each step lasted at least 8 h. The precipitate was separated by centrifugation at $10,000 \times g$ for 20 min.

MALDI-TOF analysis

The protein bands after 1D PAGE were subjected to trypsin in-gel hydrolysis. Gel pieces (2 mm^3) were excised and washed twice with 100 μl of 0.1 M NH_4HCO_3 and 40 % acetonitrile for 30 min at 37 °C, dehydrated with 100 μl of acetonitrile and air-dried. Then, they were treated with 4 μl of a 12.5 mg/ml solution of modified trypsin (Promega) in 40 mM NH_4HCO_3 and 10% acetonitrile for 16 h at 37 °C. The peptides were extracted with 8 μl of an aqueous solution of 0.5 % trifluoroacetic acid for 20 min. Aliquots (2 μl) of the sample were mixed on a steel target with 0.3 μl of a 2,5-dihydroxybenzoic acid (Bruker Daltonics, Germany) solution (75 mg/ml in 30 % acetonitrile/0.5 % trifluoroacetic acid). Mass spectra

were recorded on an Ultraflex II MALDI-ToF mass spectrometer (Bruker Daltonics, Germany) equipped with an Nd laser. The $[MH^+]$ molecular ions were measured in reflector mode; the accuracy of the mass peak measurement was 0.005 %. The fragment ion spectra were generated by laser-induced dissociation slightly accelerated by low-energy collision-induced dissociation using helium as the collision gas. The accuracy of the fragment ion mass peak measurement was 5 Da. The MS/MS fragments were identified using the BiTools software (Bruker Daltonics, Germany) and Mascot MS/MS ion search. Protein identification was performed using a peptide fingerprint search with the Mascot software (MatrixScience Inc., USA). One missed cleavage, Met oxidation and Cys-ropionamide were permitted. Protein scores greater than 49 were supposed to be significant ($p < 0.05$).

Buffer solutions for activity assays (standard buffers)

We assessed the pH effect on the enzymatic activities using the following standard buffers [29]: citric acid/sodium citrate buffer for the pH range of 1.0–5.0, sodium citrate/sodium phosphate buffer for the pH range of 5.0–7.0, sodium phosphate/sodium hydroxide buffer for the pH range of 7.0–12.0, and potassium chloride/sodium hydroxide buffer for the pH range of 12.0–13.0. The total concentration of the components in each buffer was kept at 10 mM. After determining the optimal pH conditions that corresponded to the activity peaks, we assessed the ionic strength effect on the enzymatic activities at the predetermined optimal pH conditions. In this case, the ionic strength of the solutions varied with the concentration of NaCl.

Muramidase activity assay

Muramidase activity was determined via clarifying the suspension of lyophilised *M. lysodeikticus* cells (0.5 mg/ml; Sigma, USA) after treatment with the mLDL isoforms [30, 31]. Hen egg white lysozyme (HEWL; Sigma, USA) was used as a reference lysozyme with known muramidase activity under the definite experimental conditions: at 25 °C in 20 mM Na-phosphate buffer, pH 7.4. The concentrations of both mLDL isoforms and HEWL varied from 0 to 20 $\mu\text{g/ml}$, and the sample volume was 200 μl . Incubation took place in the wells of a 96-well plate at 25 °C for 30 min. The optical densities were measured using a photometer (Multiskan Ascent, ThermoFisher Scientific, USA) at the wavelength of 405 nm. The muramidase activities of the mLDL isoforms were calculated using the following formula:

$$A \text{ (activity units)} = \left(\Delta OD_{405}^d / \Delta OD_{405}^h \right) * A^h, \quad (1)$$

where ΔOD_{405}^d and ΔOD_{405}^h are the differences in optical densities were measured before and after treatment with the mDL isoforms at different pH values and HEWL at pH 7.4, respectively, and A^h is the known muramidase activity of HEWL at pH 7.4, which was provided by the producer (in units). Negative values that were calculated using formula (1) were set to zero.

Lytic activity assay

Lytic activity was estimated by measuring the amount of total protein that was released from the *E. coli* (strain Top10) and *B. subtilis* (strain 186RT) cells following treatment with the mDL isoforms. The overnight cultures of *E. coli* and *B. subtilis* were reseeded in fresh LB medium at a dilution of 1:20 and subsequently grown until $OD_{600} = 1$. Two hundred microlitres of the cell culture was precipitated by centrifugation at $10,000 \times g$ for 2 min. Next, the pellet was resuspended in an equal volume of standard buffer followed by the addition of mDL isoforms at concentrations of 20 $\mu\text{g}/\text{ml}$. The mixture was incubated at 37 °C for 30 min. Next, the sample was diluted with distilled water to a final volume of 1 ml and then centrifuged at $10,000 \times g$ for 10 min. The supernatant was collected, and the amount of total protein released from the cells was measured using the Bradford method (QuickStart™ Bradford Protein Assay, Bio-Rad, USA) according to the manufacturer's recommendations. It is well known that many gram-negative bacteria are lysed only in the presence of ethylenediaminetetraacetic acid (EDTA), which contributes to outer membrane disruption. Therefore, we have also determined lytic activity in the presence of EDTA (5 mM) in *E. coli*.

Isopeptidase activity assay

Isopeptidase activity was determined by cleavage of the chromogenic substrate L- γ -Glu-pNA (Sigma, USA) following treatment with the mDL isoforms [32]. The mDL isoforms at concentrations of 300 $\mu\text{g}/\text{ml}$ were added to standard buffers containing L- γ -Glu-pNA at a concentration of 1 mg/ml. The solutions (each sample was 200 μl) were incubated in a 96-well plate at 37 °C for 48 h. The standard buffers containing L- γ -Glu-pNA without mDL isoforms treatment were used as control samples to exclude pH and ionic strength effects on substrate integrity. The optical densities were measured using a photometer (Multiskan Ascent) at a wavelength of 405 nm. The isopeptidase activity was calculated using the following formula:

$$A \text{ (activity units)} = (\Delta OD_{405}^d - \Delta OD_{405}^c) * 1000, \quad (2)$$

where ΔOD_{405}^d and ΔOD_{405}^c are the differences in the optical densities, which were measured before and after

treatment with mDL isoforms for the experimental and control samples, respectively, at the same pH values. Negative values that were calculated using formula (2) were set to zero.

Preparation of tryptic peptides from the mDL isoforms

Trypsin (0.1 $\mu\text{g}/\text{ml}$; Gibco®, USA) was added to the solutions containing mDL isoforms at the concentration of 200 $\mu\text{g}/\text{ml}$. The solutions were incubated at 37 °C for 1 h. Next, trypsin was inhibited by adding phenylmethanesulfonylfluoride (PMSF; Sigma, USA) at a concentration of 1 mM, and the solutions were subsequently incubated at room temperature for additional 3 h. We used a refolding buffer (20 mM NaH_2PO_4 , 150 mM NaCl) that had undergone the same preparation procedures as a control solution.

Antibacterial activity assay

The antibacterial activity of the mDL isoforms and their tryptic peptides was independently determined using the following two methods:

Method 1. Determination of the growth curves of bacteria treated with the mDL isoforms and their tryptic peptides. The overnight cultures of *E. coli* and *B. subtilis* cells were inoculated into LB medium at a dilution of 1:20 and then the mDL isoforms or their tryptic peptides were added at final concentrations varying from 0 to 20 $\mu\text{g}/\text{ml}$ along with the twofold dilutions. The cells were subsequently grown in a 96-well plate at 37 °C for 7 h. The sample volume was 200 μl . The optical density (OD_{600}) was measured every 30 min for each sample at a wavelength of 600 nm using a photometer. The total observation time was 7 h for each sample. Next, the growth curves were expressed as the time dependence of OD_{600} .

Method 2. Determination of the minimum inhibitory concentrations (MICs) of the mDL isoforms and their tryptic peptides [33]. A total of 150 μl of LB medium containing 5×10^5 CFU/ml *E. coli* or *B. subtilis* was inoculated into each well of a 96-well plate. The cells were incubated with mDL isoforms at 37 °C for 16–18 h, and their tryptic peptides at the concentrations were varied from 0 to 20 $\mu\text{g}/\text{ml}$. Next, the samples were plated onto solid LB medium in Petri dishes. The Petri dishes were incubated at 37 °C for 18 h. The growth colonies were counted, and the MICs were determined.

Fibrinolytic activity assay

Fibrinolytic activity was assayed using the fibrin plate method [34] with a slight modification. Briefly, fibrin plates were prepared by the addition of 6 mg of fibrinogen (Tehnologia-Standart, Russia) and 0.5 U of thrombin (Tehnologia-Standart, Russia) to 15 ml of 0.1 M Naphosphate buffer (pH 7.4) containing 0.15 M NaCl. The

resulting solution was immediately inoculated onto a 90-mm Petri dish. Fibrin gel formation continued at room temperature for 4 h. Droplets (5 μ l) of the solutions containing mDL isoforms at the concentration of 1 mg/ml were carefully placed on the plate and incubated at room temperature for 48 h. We measured the diameters of the lysed zones produced by each droplet. The measurements of each lysed zone were performed in three directions followed by the calculation of the mean value. The experiments were repeated independently in three fibrin plates. Percentage of stabilized fibrin in fibrin clot was determined according to the amount of soluble protein in 2 % acetic acid [35]. Unstabilized fibrin is dissolved in acid, stabilized fibrin is precipitated.

Circular dichroism

The CD spectra were recorded using a Chiroscan CD spectrophotometer (Applied Photophysics, UK). The spectra were measured between 180 and 280 nm (1 nm step) at 20 °C. A 2 mm-pathlength cell with a detachable window was used. The protein concentrations were 2 mg/ml in the buffer (5 mM Na₂HPO₄, pH 2.2, 3.2 and 6.5).

Results

Generation of the active recombinant mDL isoforms in *E. coli*

To optimise the accumulation of the mDL isoforms in *E. coli* cells, we empirically selected the strains (8 strains), media (7 media) and cultivation schemes. All optimisation procedures and an optimal refolding scheme and cultivation method are described in Additional file 4. The final yields of the active mDL isoforms were 25–30 mg per 1 litre of the bacterial culture. An electrophoregram of the isolated mDL-Ds3 is shown in Fig. 1. Well-separated bands with molecular weights of approximately 16, 28 and 44 kDa were detected. Using MALDI-TOF analysis we confirmed that these bands consisted of mDL (Additional file 5: Figure S4). Thus, we supposed that the recombinant mDL-Ds3 forms stable oligomeric complexes. Similar results were obtained for other mDL isoforms, mDL-Ds1 and mDL-Ds2 (data not shown). But by gel-filtration chromatography on Sephadex 200 mDL isoforms form only one peak corresponding to a monomer of mDL (Additional file 6: Figure S5).

Muramidase activity of the mDL isoforms

We determined the pH effect on the muramidase activity of the mDL isoforms by clarifying the suspension of lyophilised *M. lysodeikticus*. All measurements were conducted in the linear range of the decrease of absorbance *M. lysodeikticus* suspension before reaching the saturation level. It is shown in Additional file 7 at pH 6.3 without NaCl. Figure 2a shows the results of the assay for mDL-Ds3. mDL-Ds3 exhibited muramidase activity at a wide




Fig. 1 SDS-PAGE of mDL-Ds3. mDL-Ds3 was isolated using metal chelate affinity chromatography. mDL-Ds3 was heating 10 min at 95 °C with 2 % 2-mercaptoethanol. M—molecular weight marker (kDa). Electrophoresis was performed in 13.5 % acrylamide/bis gel. The gel was stained with Coomassie 250G

pH range of 5.0–12.0, with a peak at pH 6.3. We also detected an extremely high activity peak at pH 2.2. Subsequently, we analysed the effect of ionic strength on muramidase activity under these optimal pH conditions. mDL-Ds3 exhibited the greatest activity at pH 2.2 with the NaCl concentration adjusted to 150 mM (Fig. 2b) and at pH 6.3 without NaCl addition (Fig. 2c). Similar results were obtained for other mDL isoforms, mDL-Ds1 and mDL-Ds2 (Additional file 8: Figure S7). The muramidase activity of mDL isoforms at the pH 6.3 without NaCl performed in the Table 1.

Lytic activity of the mDL isoforms

We determined the pH effect on the lytic activity of the mDL isoforms by measuring the amount of total protein that was released from the gram-positive *B. subtilis* and gram-negative *E. coli* cells. mDL-Ds3 exhibited lytic activity against *B. subtilis* at the pH range of 5.0 to 9.0 (Fig. 3a). In this pH range, mDL-Ds3 possessed almost equal activity values. Therefore, to determine the effect of ionic strength on lytic activity, we selected pH 6.3, which




Fig. 2 Muramidase activity of mIDL-Ds3. Effects of pH (a) and ionic strength (b, c) on the muramidase activity of mIDL-Ds3. The activity (in units) was calculated relative to the reference enzyme HEWL according to formula (1). (n = 5)

corresponded to the conditions in the muramidase activity assay. mIDL-Ds3 exhibited the greatest activity at NaCl concentrations ranging from 0 to 200 mM (Fig. 3b). Similar results were obtained for other mIDL isoforms, mIDL-Ds1 and mIDL-Ds2 (Additional file 9: Figure S8).

We determined the lytic activity of the mIDL isoforms against *E. coli* cells. In this case, we also tested the effect of EDTA on the lytic activity of the mIDL isoforms. It is well known that EDTA contributes to outer membrane disruption, providing access to peptidoglycan in gram-negative bacteria [36]. Peptidoglycan is known to serve as a substrate for lysozymes. The mIDL isoforms exhibited the greatest lytic activity without EDTA at the pH range of 5.0–9.0 (data not shown). In the presence of EDTA (5 mM), the greatest lytic activity slightly shifted toward alkaline conditions with the pH range


of 6.0–10.0. Therefore, as for *B. subtilis*, we selected pH 6.3 to determine the effect of ionic strength on lytic activity. The mIDL isoforms exhibited the greatest lytic activity at 0 M NaCl without EDTA and at 0.3 M NaCl with EDTA (Additional file 9: Figure S8). The lytic activity of mIDL isoforms at the pH 6.3 without NaCl and EDTA performed in the Table 1.

Isopeptidase activities of the mIDL isoforms

We determined the pH effect on the isopeptidase activity of the mIDL isoforms based on the production of p-nitroanilide L-γ-Glu-pNA, which is measured by the absorbance at 405 nm. Figure 4a shows the results of the assay for mIDL-Ds3. mIDL-Ds3 exhibited isopeptidase activity in the pH range of 4.5–7.0, with peak activity at pH 5.5. Subsequently, we analysed the effect ionic strength

Table 1 Comparison of the mIDL fermentative activities and half-maximal diapasones

	Muramidase activity (in lysozyme units)	Lytic activity	Isopeptidase activity			Half-maximal pH and I values for		
			in activity units	K_{mV} , μM	$k_{catV} \times 10^{-2} s^{-1}$	muramidase activity	lytic activity	isopeptidase activity
mIDL-Ds1	5200 ± 450	0.079 ± 0.005	850 ± 70	40	7	pH 2.5–3, I = 0–0.25 M;	pH 4.5–10	pH 4.5–7.5
mIDL-Ds2	2450 ± 250	0.035 ± 0.003	660 ± 60	50	8	pH 4.5–12, I = 0–0.05 M	I = 0–0.4 M	I = 0–0.1 M
mIDL-Ds3	10,000 ± 600	0.136 ± 0.005	1780 ± 160	20	5			



on isopeptidase activity at pH 5.5. mDL-Ds3 exhibited the greatest activity without the addition of NaCl (Fig. 4b). Similar results were obtained for the other destabilase isoforms, mDL-Ds1 and mDL-Ds2 (Additional file 10: Figure S9). The isopeptidase activity of mDL isoforms at the pH 5.5 without NaCl performed in the Table 1.

Antimicrobial activity of the mDL isoforms

We determined the antimicrobial activity of the mDL isoforms and their tryptic peptides (mDL-Ds1t, mDL-Ds2t, mDL-Ds3t) using two methods. The tryptic peptides were generated to test whether the mDL isoforms exhibit anti-bacterial activity independent of their enzymatic activities. To eliminate the influence of an intact protein, we measured the muramidase activity of tryptic peptides. This mixture did not provide the enzymatic activity.


According to Method 1, we determined the growth curves of bacteria that were exposed to the enzymes and their tryptic peptides at different concentrations. The growth of both gram-positive and gram-negative bacteria was inhibited by mDL isoforms and their tryptic


peptides. Notably, the tryptic peptides of all mDL isoforms exhibited more efficient bacterial growth inhibition than the whole enzymes did. Figure 5 shows the growth curves for mDL-Ds3 and mDL-Ds3t. Similar results were obtained for the other mDL isoforms: mDL-Ds1 and mDL-Ds2 (data not shown).

In Method 2, we determined the MICs of the mDL isoforms and their tryptic peptides (Table 2). Fewer MICs were determined for the whole mDL isoforms and their tryptic peptides in *B. subtilis* than for *E. coli*. Moreover, for both bacterial species, the tryptic peptides had fewer MICs than the corresponding whole enzymes. These data confirm the results obtained with Method 1.

Fibrinolytic activity of the mDL isoforms

Fibrinolytic activity was determined by measuring the diameters of the lysed zones that resulted from the placement of droplets of the enzyme-containing solutions on fibrin plates. In this case, we investigated not only intact mDL isoforms but also heat-inactivated (at 95 °C for 2 h) enzymes and their tryptic peptides to test whether the





fibrinolytic activity was enzymatic. We determined that only the intact mIDL isoforms exhibited fibrinolytic activity. All of the intact mIDL isoforms caused lysed zones with equal diameters (6 ± 1 mm). A representative image of one such plate is shown in Fig. 6a.

Also, we performed the SDS-PAGE analysis of lysed zones (line 1, Fig. 6b). This fibrin gel was stabilized on 70 %. Solid zone of gel (untreated zone) was dissolved in 2 % acetic acid. Soluble fraction (line 2) and precipitate (dissolved in 5 % SDS, line 3) were analyzed by SDS-PAGE, too. We found the γ - γ fibrin chain only in insoluble fraction of fibrin. This chain is absent in soluble control fraction and fraction from lysed zone by mIDL-Ds3. Then we analyzed the stabilized fibrin treated by mIDL-Ds3 (Fig. 6c). We incubated stabilized fibrin clot with mIDL-Ds3 at 37 °C for 96 h. As the control we used the buffer without mIDL. We found the γ - γ fibrin chain only in insoluble fraction of control sample of stabilized fibrin (lane 4).

Discussion


In this study, we obtained all known isoforms of mIDL (mIDL-Ds1, mIDL-Ds2, mIDL-Ds3) from medicinal leeches in the form of recombinant proteins in *E. coli*. We optimised the expression, isolation and purification procedures and obtained a fivefold increase in the yield of the recombinant mIDL isoforms compared with previous studies. This allowed us to investigate the enzymatic and antibacterial activities of these isoforms.

MALDI-TOF analysis data suggested that the recombinant mIDL isoforms form stable oligomeric complexes (Additional file 5: Figure S4). We have identified pure mIDL and the dimer and trimer complexes. According to gel-filtration chromatography (Additional file 6: Figure S5), mIDL forms have only one peak, corresponding to a mIDL's-monomer. This fact does not explain the origin of these oligomeric structures. We suppose that the total protein from purified mIDL consists mostly of monomeric form, and other oligomers represent only a small part of the total protein. However observations about oligomeric forms are in agreement with previous investigations that showed that some i-lysozymes could form active dimer and trimer complexes. However, the oligomeric complexes of the destabilase isoforms were not disrupted in the solution with high ionic strength, in contrast to other i-type lysozymes [17].

Furthermore, we investigated lysozyme (muramidase and lytic), isopeptidase and antimicrobial activities of the recombinant mIDL isoforms. The greatest muramidase activity of the mIDL isoforms was detected within the pH range of 5.0–12.0. Surprisingly, we also detected the peak of the muramidase activity at extremely acidic pH 2.2. Most of the known i-type lysozymes exhibit the greatest muramidase activity within the pH range of 6.0–8.0 [17], but these lysozymes have not yet been shown to possess activity at the extremely acidic pH. We have analysed the circular dichroism (CD) spectra of mIDL isoforms at different pH conditions: 2.2 and 6.5 are corresponds the maximum of muramidase activity,

Table 2 Minimum inhibitory concentrations (MICs) of the recombinant mIDL isoforms and their tryptic peptides

	mIDL-Ds1	mIDL-Ds2	mIDL-Ds3	mIDL-Ds1t	mIDL-Ds2t	mIDL-Ds3t
MIC (µg/ml), <i>E.coli</i>		2.5			1.3	
MIC (µg/ml), <i>B.subtilis</i>		1.3			0.6	



3.2—minimum of muramidase activity (Additional file 11: Figure S10). All probes of the mIDL exhibited similar CD spectra. However, the spectra are shifted to the long wavelength waves with increasing pH to all isoforms of mIDL. Consequently, we suppose that the conformation of the protein does not significantly affect the change in activity.

The ionic strength effect on muramidase activity differed for the different optimal pH values. The increase in NaCl concentration at pH 6.3 strongly inhibited the muramidase activity of the mIDL isoforms, a result that is in a good agreement with those obtained for mIDL isolated from the salivary gland secretion.

To test the lytic activity, we used gram-positive bacteria *B. subtilis* and gram-negative bacteria *E. coli*. The bacterial cell wall contains peptidoglycan, a main substrate for lysozyme. Peptidoglycan of gram-positive bacteria is located outside of the cell, whereas peptidoglycan of gram-negative bacteria is hidden by the outer membrane. EDTA disrupts the outer membrane in gram-negative bacteria, facilitating the enzyme's access to peptidoglycan [36]. The mIDL isoforms exhibited the greatest lytic activity within the pH range of 5.0–9.0 for both *B. subtilis* and *E. coli*. These data are in agreement those of the previous study. In the presence of EDTA, the optimal pH range shifted toward an alkaline pH. In contrast to the muramidase activity, we have not detected the lytic activity at the acidic pH values.

The isopeptidase activity of the mIDL isoforms was determined by the production of p-nitroanilide from L-γ-Glu-pNA, which was detected by the absorbance at 405 nm. This chromogenic substrate is mainly used to study gamma-glutamyl transpeptidase and possesses a low specificity for isopeptidase. Therefore, the optimal conditions for cleavage of this substrate have been shown to require high enzyme concentrations (300–500 μg/ml) and a long incubation time (above 48 h). The mIDL isoforms exhibited isopeptidase activity in a rather narrow range of pH values (from 5.0 to 6.5). This is in agreement with the previous observations for other i-type lysozymes that possessed isopeptidase activity. We revealed that isopeptidase activity was very sensitive to the ionic strength. It has not been detected at NaCl concentrations above 0.3 M. For isopeptidase activity we measured K_m and k_{kat} . It was found that for all isoforms $K_m = 20\text{--}50\ \mu\text{M}$ and $k_{kat} = 5\text{--}8 \times 10^{-2}\ \text{s}^{-1}$. So high K_m and low k_{kat} can be explained also by low specificity of substrate. Although these values are comparable to those obtained previously for mIDL-Ds2 ($K_m = 50\ \mu\text{M}$, $k_{kat} = 0.1 \times 10^{-2}\ \text{s}^{-1}$) [13] and TJL ($K_m = 20\ \mu\text{M}$, $k_{kat} = 0.2 \times 10^{-4}\ \text{s}^{-1}$) [32].

For all fermentative activities we found the half-maximal pH and I values (Table 1). These values were similar for all mIDL isoforms: for lytic activity—pH 4.5–10 and $I = 0\text{--}0.4\ \text{M}$, for isopeptidase activity—pH 4.5–7.5 and $I = 0\text{--}0.1\ \text{M}$. For muramidase activity mIDL had two ranges: pH 2.5–3 and $I = 0\text{--}0.25\ \text{M}$, pH 4.5–12 and $I = 0\text{--}0.05\ \text{M}$. This information allows us to suggest the similarity of their enzymatic properties. Previous studies have demonstrated the antimicrobial activity of heat-inactivated mIDL [19]. This antimicrobial effect was also observed with synthetic amphipathic fragments of mIDL [18]. We used the mIDL isoforms and their tryptic peptides to investigate antimicrobial activity. We revealed the inhibition of bacterial growth (*E. coli* and *B. subtilis*) in the presence of the mIDL isoforms and their tryptic peptides. The tryptic peptides exhibited more efficient inhibition of bacterial growth than the entire enzymes. This was confirmed by MIC determination. The MICs of tryptic peptides were lower than those of the entire mIDL isoforms. The antimicrobial activity detected in the tryptic peptides of the mIDL isoforms confirmed that this activity is non-enzymatic. The antimicrobial activity that was independent of muramidase activity has been shown for other invertebrate lysozymes, but the mechanism of this action remains unclear.

For the first time, we have revealed that recombinant mIDL isoforms exhibit fibrinolytic activity. We determined that only the intact mIDL isoforms possess fibrinolytic activity. Neither tryptic peptides nor heat-inactivated protein exhibited fibrinolytic activity, suggesting that this activity is enzymatic and requires structural organisation of the active centre.

Conclusions

We isolated all of the currently known mIDL isoforms from medicinal leeches and demonstrated the enzymatic activities of all of the recombinant isoforms. All of the mIDL isoforms exhibited almost identical patterns of pH and ionic strength effects on the activities. We also found that the antimicrobial activity of the mIDL isoforms is muramidase activity-independent and non-enzymatic. We found that the tryptic peptides of the mIDL isoforms exhibited more efficient inhibition of bacterial growth and had lower MICs than the whole enzymes did. We also showed that only the whole mIDL isoforms possess fibrinolytic activity.

Availability of data and materials

The data sets supporting the results of this article are included within the article and its additional files.

Additional files

Additional file 1: Figure S1. Comparison of amino acid sequences of mIDL isoforms. Catalytic residues responsible for muramidase activity are indicated with red point, and those for the isopeptidase activity with blue point. (JPG 51 kb)

Additional file 2: Table S1. List of oligonucleotides used. (XLS 30 kb)

Additional file 3: Scheme for de novo synthesising from oligonucleotides DNA fragments that encode the mIDL-Ds1, 2, 3 (optymized for *E. coli*) and map of plasmid, encoding mIDL.

Figure S2. Fragment of pET15MCS plasmid containing multicloning sites. PT7—promoter of late genes of bacteriophage T7; RBS—ribosome binding site; ATG—start codon; MCS—multiple cloning site; stop—stop codon; 6His—fragment encoding six histidines; tromb—fragment encoding the recognition site of thrombin. **Figure S3.** A map of the plasmid pET15/Dest. PT7—promoter of bacteriophage T7 late genes; *dest*—fragment encoding the mIDL isoforms; 6His—region encoding the hexa-histidine motive; stop—translation terminator; term—a transcription terminator; *bla*—beta-lactamase gene; pBR322ori—an origin of replication of plasmid pBR322; *lacI*—gene *lacI* of *E. coli*; tromb—sequence encoding the recognition site of thrombin. (PDF 119 kb)

Additional file 4: Detailed scheme of isolating mIDL isoforms from inclusion bodies and their optimisation of renaturation by dialysis.

mIDL-Ds1, 2, 3 were isolated using metal chelate affinity chromatography under denaturing conditions. Optimisation of mIDL isoforms accumulation in *E. coli* cells. We empirically selected the strains (8 strains), media (7 media) and cultivation schemes. Table S2. Accumulation levels of the recombinant mIDL isoforms in inclusion bodies from different *E. coli* strains. Accumulation levels are expressed in mg of protein per litre of culture ($n = 3$). Table S3. Accumulation levels of the mIDL in inclusion bodies from *E. coli* BL21(DE3)-gold in different culture media. Accumulation levels are expressed in mg of protein per litre of culture ($i = 3$). (PDF 64 kb)

Additional file 5: Figure S4. MALDI-TOF analysis of mIDL isoforms. (PDF 388 kb)

Additional file 6: Figure S5. Profiles of gel-chromatography analysis of mIDL isoforms. (PDF 129 kb)

Additional file 7: Figure S6. Absorbance at 405 nm of *M. lysodeikticus* suspension during mIDL-Ds3 treatment at 25 °C for 20 min in 5 mM Na-phosphate buffer pH 6.3. ($n = 3$). (PDF 50 kb)

Additional file 8: Figure S7. Muramidase activity of mIDL isoforms. Effects of pH (a) and ionic strength (b, c) on the muramidase activity of mIDL-Ds1. Muramidase activity of mIDL-Ds2. Effects of pH (d) and ionic strength (e, f) on the muramidase activity of mIDL-Ds2. The activity

(in units) was calculated relative to the reference enzyme HEWL according to formula (1). ($n = 5$). (PDF 106 kb)

Additional file 9: Figure S8. Lytic activity of mIDL isoforms. Effects of pH (a) and ionic strength (b) on the lytic activity of mIDL-Ds1. Effects of pH (c) and ionic strength (d) on the lytic activity of mIDL-Ds2. The activity was expressed as the concentration of protein released from the cells of *B. subtilis*. Effects of pH (e) and ionic strength (f) on the lytic activity of mIDL-Ds1 in the presence of 5 mM EDTA. The activity was expressed as the concentration of protein released from the cells of *E. coli*. Effects of pH (g) and ionic strength (h) on the lytic activity of mIDL-Ds2 in the presence of 5 mM EDTA. The activity was expressed as the concentration of protein released from the cells of *E. coli*. Effects of pH (i) and ionic strength (j) on the lytic activity of mIDL-Ds3 in the presence of 5 mM EDTA. The activity was expressed as the concentration of protein released from the cells of *E. coli*. ($n = 5$). (PDF 126 kb)

Additional file 10: Figure S9. Isopeptidase activity of mIDL isoforms. The effect of pH (a) and ionic strength (b) at pH 5.5 on the isopeptidase activity of mIDL-Ds1. The effect of pH (c) and ionic strength (d) at pH 5.5 on the isopeptidase activity of mIDL-Ds2. Isopeptidase activity was calculated according to formula (2). ($n = 5$). (PDF 100 kb)

Additional file 11: Figure S10. CD spectra of mIDL isoforms at different pH conditions (2.2, 3.2, 6.5). (PDF 84 kb)

Abbreviations

HEWL: Hen egg white lysozyme; MIC: Minimum inhibitory concentration; CFU: Colony-forming unit; OD: Optical density; EDTA: Ethylenediaminetetraacetic acid; PMSF: Phenylmethanesulfonylfluoride; CD: Circular dichroism.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ASK performed research (enzymatic characterization), analyzed data, wrote the manuscript first draft. VAM designed, performed (protein purification) and supervised research, wrote the final version of the manuscript. IPB designed and supervised research. VNL designed and supervised research. All authors read and approved the final manuscript.

Acknowledgements

The reported study was supported by the Russian Science Foundation (project No. 14-14-00696). The authors would like to thank Dariya Matushkina and Olga Pobeguts (Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia), Sergey Kovalchuk (Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia) for the MALDI-TOF analyses and Anna Varizhuk (Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia) for the CD analyses.

Author details

¹Federal Research and Clinical Center of Physical-Chemical Medicine, Malaya Pirogovskaya, 1a, Moscow 119435, Russia. ²Biological Faculty, M. V. Lomonosov Moscow State University, Moscow 119991, Russia.

Received: 23 July 2015 Accepted: 17 November 2015

Published online: 21 November 2015

References

- Godekmerdan A, Arusan S, Bayar B, Saglam N. Medicinal leeches and hirudotherapy. *Turkiye Parazitol Derg.* 2011;35(4):234–9.
- Hyson JM. Leech therapy: A history. *J Hist Dent.* 2005;53(1):25–7.
- Hildebrandt JP, Lemke S. Small bite, large impact—saliva and salivary molecules in the medicinal leech. *Hirudo Medicinalis Naturwissenschaften.* 2011;98(12):995–1008.
- Liang JQ, Mi SQ, Wang NS. Anticoagulative effect and antiplatelet aggregation effect of combination of Hirudo and Tabanus on rat model of blood stasis syndrome. *Zhong Yao Cai.* 2009;32(9):1347–50.
- Basanova AV, Baskova IP, Zavalova LL. Vascular-platelet and plasma hemostasis regulators from bloodsucking animals. *Biochemistry (Mosc).* 2002;67(1):143–50.

6. Baskova IP, Khalil S, Nikonov GI. Effect of the salivary gland secretion of medicinal leeches *Hirudo medicinalis* on the external and internal mechanisms of blood coagulation. *Bull Exp Biol Med*. 1984;98(8):142–3.
7. Rigbi M, Levy H, Eldor A, Iraqi F, Teitelbaum M, Orevi M, et al. The saliva of the medicinal leech *Hirudo medicinalis*—II. Inhibition of platelet aggregation and of leukocyte activity and examination of reputed anaesthetic effects. *Comp Biochem Physiol C*. 1987;88(1):95–8.
8. Feng GJ, Zhu ZG, Yu CL, Zhang Q, Chen NN, Lei LS, et al. Study of anticoagulant activity of ethanol extracts from leech in vitro. *Zhong Yao Cai*. 2007;30(8):909–11.
9. Press A. A case of haemorrhage due to application of leeches. *Harefuah*. 1948;34(4):50.
10. Baskova IP, Nikonov GI. Destabilase: An enzyme of medicinal leech salivary gland secretion hydrolyzes the isopeptide bonds in stabilized fibrin. *Biochemistry (Mosc)*. 1985;50(3):424–31.
11. Baskova IP, Nikonov GI, Zavalova LL, Larionova NI. Kinetics of L-gamma-Glu-pNA hydrolysis by destabilase, the enzyme from the medicinal leech *Hirudo medicinalis*. *Biochemistry (Mosc)*. 1990;55(4):674–9.
12. Zavalova LL, Nikonov GI, Kuzina EV, Popova G, Baskova IP. A dimer of fragment D from stabilized fibrin—a substrate for the destabilase enzyme (gamma-glutamyl-epsilon-lysyl-isopeptidase). *Biochemistry (Mosc)*. 1991;56(1):115–24.
13. Zavalova LL, Lazarev VN, Levitsky SA, Yudina TG, Baskova IP. Destabilase-lysozyme of medicinal leech. Multifunctionality of recombinant protein. *Biochemistry (Mosc)*. 2010;75(9):1173–81.
14. Zavalova LL, Kuzina EV, Levina NB, Baskova IP. Monomerization of fragment DD by destabilase from the medicinal leech does not alter the N-terminal sequence of the gamma-chain. *Thromb Res*. 1993;71(3):241–4.
15. Baskova IP, Zavalova LL, Basanova AV, Aquejof OM, Azougagh-Oualane F, Doutremepuich C. Antithrombotic effect of piavit—a substance from the medicinal leech (*Hirudo medicinalis*), containing prostanoid and destabilase fractions. *Biochemistry (Mosc)*. 1995;60(11):1775–83.
16. Zavalova LL, Baskova IP, Lukyanov SA, Sass AV, Snezhkov EV, Akopov SB, et al. Destabilase from the medicinal leech is a representative of a novel family of lysozymes. *Biochim Biophys Acta*. 2000;1478(1):69–77.
17. Callewaert L, Michiels CW. Lysozymes in the animal kingdom. *J Biosci*. 2010;35(1):127–60.
18. Zavalova LL, Yudina TG, Artamonova II, Baskova IP. Antibacterial non-glycosidase activity of invertebrate destabilase-lysozyme and of its helical amphipathic peptides. *Chemotherapy*. 2006;52(3):158–60.
19. Yudina TG, Guo D, Piskunkova NF, Pavlova IB, Zavalova LL, Baskova IP. Antifungal and antibacterial functions of medicinal leech recombinant destabilase-lysozyme and its heated-up derivative. *Front Chem Sci Eng*. 2012;6(5):203–9.
20. Zavalova LL, Antipova NV, Fadeeva Iu I, Pavliukov MS, Pletneva NV, Pletnev VZ, et al. Catalytic sites of medicinal leech enzyme destabilase-lysozyme (Mdl). Structure-functional correlation. *Bioorg Khim*. 2012;38(2):229–33.
21. Goto T, Abe Y, Kakuta Y, Takeshita K, Imoto T, Ueda T. Crystal structure of Tapes japonica Lysozyme with substrate analogue: Structural basis of the catalytic mechanism and manifestation of its chitinase activity accompanied by quaternary structural change. *J Biol Chem*. 2007;282(37):27459–67.
22. Abe Y, Ueda T. Structure and function of Tapes japonica lysozyme. *Seikagaku*. 2009;81(4):314–9.
23. Baskova IP, Nikonov GI. Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity. *Blood Coagul Fibrinolysis*. 1991;2(1):167–72.
24. Fradkov A, Berezchnoy S, Barsova E, Zavalova L, Lukyanov S, Baskova I, et al. Enzyme from the medicinal leech (*Hirudo medicinalis*) that specifically splits endo-epsilon-(gamma-Glu)-Lys isopeptide bonds: cDNA cloning and protein primary structure. *FEBS Lett*. 1996;390(2):145–8.
25. Zavalova LL, Artamonova II, Berezchnoy SN, Tagaev AA, Baskova IP, Andersen J, et al. Multiple forms of medicinal leech destabilase-lysozyme. *Biochem Biophys Res Commun*. 2003;306(1):318–23.
26. Zavalova L, Lukyanov S, Baskova I, Snezhkov E, Akopov S, Berezchnoy S, et al. Genes from the medicinal leech (*Hirudo medicinalis*) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots. *Mol Genet*. 1996;253(1–2):20–5.
27. Zavalova LL, Baskova IP, Barsova EV, Snezhkov EV, Akopov SB, Lopatin SA. Recombinant destabilase-lysozyme: Synthesis de novo in *E. coli* and action mechanism of the enzyme expressed in *Spodoptera frugiperda*. *Biochemistry (Mosc)*. 2004;69(7):776–81.
28. Zavalova LL, Baskova IP, Barsova EV, Snezhkov EV, Akopov SB, Lopatin SA. Recombinant destabilase-lysozyme: Synthesis de novo in *E. coli* and Action Mechanism of the enzyme expressed in *spodoptera frugiperda*. *Biochemistry (Mosc)*. 2003;69(7):952–8.
29. Harned HS, Robinson RA. Multicomponent electrolyte solutions. 1st ed. Oxford: Pergamon Press; 1968.
30. Yue X, Liu B, Xue Q. An i-type lysozyme from the Asiatic hard clam *Meretrix meretrix* potentially functioning in host immunity. *Fish Shellfish Immunol*. 2011;30(2):550–8.
31. Shugar D. The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme. *Biochim Biophys Acta*. 1952;8(3):302–9.
32. Takeshita K, Hashimoto Y, Ueda T, Imoto T. A small chimerically bifunctional monomeric protein: Tapes japonica lysozyme. *Cell Mol Life Sci*. 2003;60(9):1944–51.
33. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat Protoc*. 2008;3(2):163–75.
34. Astrup T, Mullertz S. The fibrin plate method for estimating fibrinolytic activity. *Arch Biochem Biophys*. 1952;40(2):346–51.
35. Pisano JJ, Finlayson JS, Peyton MP. Cross-link in fibrin polymerized by factor 13: Epsilon-(gamma-glutamyl)lysine. *Science*. 1968;160(3830):892–3.
36. Goldschmidt MC, Wyss O. The role of tris in EDTA toxicity and lysozyme lysis. *J Gen Microbiol*. 1967;47(3):421–31.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

